PYC Stock Overview
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Physiomics Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.013 |
| 52 Week High | UK£0.033 |
| 52 Week Low | UK£0.009 |
| Beta | 1.78 |
| 1 Month Change | 0% |
| 3 Month Change | -12.90% |
| 1 Year Change | -54.24% |
| 3 Year Change | -79.39% |
| 5 Year Change | -55.74% |
| Change since IPO | -99.42% |
Recent News & Updates
Recent updates
It's Unlikely That Shareholders Will Increase Physiomics Plc's (LON:PYC) Compensation By Much This Year
Nov 15
Here's Why We Think Physiomics Plc's (LON:PYC) CEO Compensation Looks Fair
Nov 17Here's Why Shareholders Will Not Be Complaining About Physiomics Plc's (LON:PYC) CEO Pay Packet
Nov 16What Can We Conclude About Physiomics' (LON:PYC) CEO Pay?
Feb 08
Shareholder Returns
| PYC | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 12.5% | -8.6% | -0.9% |
| 1Y | -54.2% | -45.7% | -1.8% |
Return vs Industry: PYC underperformed the UK Life Sciences industry which returned -45.7% over the past year.
Return vs Market: PYC underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| PYC volatility | |
|---|---|
| PYC Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PYC's share price has been volatile over the past 3 months.
Volatility Over Time: PYC's weekly volatility has decreased from 18% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 10 | Peter Sargent | www.physiomics.co.uk |
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine.
Physiomics Plc Fundamentals Summary
| PYC fundamental statistics | |
|---|---|
| Market cap | UK£1.83m |
| Earnings (TTM) | -UK£451.26k |
| Revenue (TTM) | UK£641.73k |
2.8x
P/S Ratio-4.1x
P/E RatioIs PYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYC income statement (TTM) | |
|---|---|
| Revenue | UK£641.73k |
| Cost of Revenue | UK£1.14m |
| Gross Profit | -UK£500.86k |
| Other Expenses | -UK£49.61k |
| Earnings | -UK£451.26k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0033 |
| Gross Margin | -78.05% |
| Net Profit Margin | -70.32% |
| Debt/Equity Ratio | 0% |
How did PYC perform over the long term?
See historical performance and comparison